

# Mohammad Hossein Harirchian

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2949738/publications.pdf>

Version: 2024-02-01

56  
papers

784  
citations

687363

13  
h-index

552781

26  
g-index

56  
all docs

56  
docs citations

56  
times ranked

1411  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dietary fish intake and the risk of multiple sclerosis: a systematic review and meta-analysis of observational studies. <i>Nutritional Neuroscience</i> , 2022, 25, 681-689.	3.1	4
2	Epidemiology of familial multiple sclerosis in Iran: a national registry-based study. <i>BMC Neurology</i> , 2022, 22, 76.	1.8	8
3	Quantification of Blood-Brain-Barrier Permeability Dysregulation and Inflammatory Activity in MS Lesions by Dynamic-Contrast Enhanced MR Imaging. <i>Basic and Clinical Neuroscience</i> , 2022, 13, 117-128.	0.6	3
4	Prescription trends of disease-modifying treatments for multiple sclerosis in Iran over the past 30 years. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 61, 103777.	2.0	6
5	COVID-19 and its Outcomes in Multiple Sclerosis Patients. <i>Caspian Journal of Neurological Sciences</i> , 2022, 8, 98-103.	0.2	1
6	Effects of Nonconsecutive Sessions of Transcranial Direct Current Stimulation and Stationary Cycling on Walking Capacity in Individuals With Multiple Sclerosis. <i>International Journal of MS Care</i> , 2022, 24, 202-208.	1.0	4
7	SARS-CoV-2 and Stroke Characteristics. <i>Stroke</i> , 2021, 52, e117-e130.	2.0	51
8	The trend of incidence, prevalence, and DALY of multiple sclerosis in the Middle East and Northern Africa region compared to global, West Europe and, Iran's corresponding values during 1990â€“2017: Retrieved from global burden of diseases data. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 52, 102949.	2.0	5
9	Developing a Multi-channel Beamformer by Enhancing Spatially Constrained ICA for Recovery of Correlated EEG Sources. <i>Journal of Biomedical Physics and Engineering</i> , 2021, 11, 205-214.	0.9	2
10	Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study. <i>Caspian Journal of Internal Medicine</i> , 2021, 12, 263-274.	0.2	1
11	Safety and efficacy of memantine for multiple sclerosis-related fatigue: A pilot randomized, double-blind placebo-controlled trial. <i>Journal of the Neurological Sciences</i> , 2020, 414, 116844.	0.6	5
12	Inhibition of protein disulfide isomerase has neuroprotective effects in a mouse model of experimental autoimmune encephalomyelitis. <i>International Immunopharmacology</i> , 2020, 82, 106286.	3.8	5
13	Necrotizing fungal osteomyelitis and fingolimod, 4 years after treatment with fingolimod. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 41, 102021.	2.0	4
14	The effects and side effects of laquinimod for the treatment of multiple sclerosis patients: a systematic review and meta-analysis of clinical trials. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 611-622.	1.9	4
15	Impact of an Existential-Spiritual Intervention Compared with a Cognitive-Behavioral Therapy on Quality of Life and Meaning in Life among Women with Multiple Sclerosis. <i>Iranian Journal of Psychiatry</i> , 2020, 15, 322-330.	0.7	1
16	Computer-aided classifying and characterizing of methamphetamine use disorder using resting-state EEG. <i>Cognitive Neurodynamics</i> , 2019, 13, 519-530.	4.0	26
17	Increased expression of endoplasmic reticulum stress-related caspase-12 and CHOP in the hippocampus of EAE mice. <i>Brain Research Bulletin</i> , 2019, 147, 174-182.	3.0	26
18	C/EBP homologous protein investigation in the serum and cerebro-spinal fluid of relapsing-remitting multiple sclerosis patients. <i>Journal of Clinical Neuroscience</i> , 2019, 59, 51-54.	1.5	2

#	ARTICLE	IF	CITATIONS
19	A systematic review and meta-analysis of randomized controlled trials to evaluating the trend of cytokines to vitamin A supplementation in autoimmune diseases. <i>Clinical Nutrition</i> , 2019, 38, 2038-2044.	5.0	4
20	Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: A literature review. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 350-363.	2.0	111
21	Calcitriol, but not FGF23, increases in CSF and serum of MS patients. <i>Journal of Neuroimmunology</i> , 2019, 328, 89-93.	2.3	5
22	The trend of incidence and burden of neurological disease in Iran between 1990 and 2017: Based on global burden of disease estimations. <i>Iranian Journal of Neurology</i> , 2019, 18, 134-142.	0.5	3
23	Minocycline decreases CD36 and increases CD44 in LPS-induced microglia. <i>Journal of Neuroimmunology</i> , 2018, 317, 95-99.	2.3	12
24	Safety and Efficacy of Nanocurcumin as Add-On Therapy to Riluzole in Patients With Amyotrophic Lateral Sclerosis: A Pilot Randomized Clinical Trial. <i>Neurotherapeutics</i> , 2018, 15, 430-438.	4.4	90
25	Worldwide prevalence of familial multiple sclerosis: A systematic review and meta-analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 43-47.	2.0	52
26	The effect of minocycline on indolamine 2, 3 dioxygenase expression and the levels of kynurenic acid and quinolinic acid in LPS-activated primary rat microglia. <i>Cytokine</i> , 2018, 107, 125-129.	3.2	8
27	Differential Expression of Klotho in the Brain and Spinal Cord is Associated with Total Antioxidant Capacity in Mice with Experimental Autoimmune Encephalomyelitis. <i>Journal of Molecular Neuroscience</i> , 2018, 64, 543-550.	2.3	6
28	Cerebral Hyperperfusion Syndrome, an Unusual but Disastrous Complication of Carotid Recanalization: A Case Report. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, e17-e19.	1.6	2
29	Role of HHV-6 subtypes in accelerating EAE progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E12126-E12126.	7.1	2
30	Evaluation of the risk of cervical cancer in patients with Multiple Sclerosis treated with cytotoxic agents: A cohort study. <i>Iranian Journal of Neurology</i> , 2018, 17, 64-70.	0.5	3
31	Metalloproteinase 9 as a biomarker of progressive multifocal leukoencephalopathy development in multiple sclerosis patients receiving natalizumab. <i>Annals of Neurology</i> , 2017, 82, 647-647.	5.3	1
32	Soluble CD40 ligand derived from serum is not correlated with early MS. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 14, 29-31.	2.0	4
33	The first attack of multiple sclerosis presented immediately after voluntary and intensive weight loss: A case series. <i>Iranian Journal of Neurology</i> , 2017, 16, 41-42.	0.5	2
34	Retinyl Palmitate Supplementation Modulates T-bet and Interferon Gamma Gene Expression in Multiple Sclerosis Patients. <i>Journal of Molecular Neuroscience</i> , 2016, 59, 360-365.	2.3	19
35	<sup>1</sup> H-MRS metaboliteâ€™s ratios show temporal alternation in temporal lobe seizure: Comparison between interictal and postictal phases. <i>Epilepsy Research</i> , 2016, 128, 158-162.	1.6	4
36	Memantine for Prophylactic Treatment of Migraine Without Aura: A Randomized Doubleâ€™Blind Placeboâ€™Controlled Study. <i>Headache</i> , 2016, 56, 95-103.	3.9	57

#	ARTICLE	IF	CITATIONS
37	Neuromyelitis optica and pregnancy. Acta Neurologica Belgica, 2016, 116, 431-438.	1.1	9
38	Trends of quality of life changes in amyotrophic lateral sclerosis patients. Journal of the Neurological Sciences, 2016, 368, 35-40.	0.6	17
39	Multiple sclerosis influences on the augmentation of serum Klotho concentration. Journal of the Neurological Sciences, 2016, 362, 69-72.	0.6	12
40	Granulocyte Colony-Stimulating Factor for Amyotrophic Lateral Sclerosis: A Randomized,		

#	ARTICLE	IF	CITATIONS
55	Non-invasive brain mapping of motor-related areas of four limbs in patients with clinically isolated syndrome compared to healthy normal controls. <i>Journal of Clinical Neuroscience</i> , 2010, 17, 736-741.	1.5	12
56	A case of choreoacanthocytosis with marked weight loss: Impact of orolingual dyskinesia. <i>Neurology India</i> , 2006, 54, 296.	0.4	3